Tag Archives: glucagon like peptide 1

Dipeptidyl Peptidase IV Inhibitor. Januvia Sitagliptin in Type 2 Diabetes Treatment

There is considerable interest in the dipeptidyl peptidase IV (DPP-IV) medications for type 2 diabetes treatment because, as a class, dipeptidyl peptidase IV drugs such as Januvia 25 mg pills (sitagliptin) appear to be well tolerated by people on type 2 diabetes treatment and can be used efficiently as monotherapy or as combination therapy together with Metformin (Glucophage, Fortamet, Glumetza drugs) oral diabetic medications. Beneficial effects of Januvia (sitagliptin) and dipeptidyl peptidase IV inhibitors as class on the pancreas beta-cell function raise the possibility that these sitagliptin agents of DPP-IV inhibitors may be able to modify the natural history of type 2 diabetes, given that Januvia used in proper type 2 diabetes treatment plan.

» Read more

Pramlintide (Symlin) for Type 1 Diabetes Treatment and Type 2 Diabetes Treatment

One of the most frustrating side effects associated with overall blood glucose control improvement in people with diabetes using intensive insulin therapy is weight gain. The addition of Symlin (pramlintide) to intensive insulin therapy for diabetes treatment improves long-term blood glucose control beyond that obtained with insulin therapy alone and significantly decreases weight gain and risk of hypoglycemia events. Pramlintide (Symlin) is an analogue to the native amylin.

» Read more

Exenatide (Byetta) for Type 2 Diabetes Treatment

Exenatide drug under brand Byetta is a novel GPL-1 (Glucagon-like Peptide-1) incretin mimetic hormone that has been FDA approved for use in poorly managed Type 2 diabetes individuals using sulfonylureas and metformin pills. Glucagon-like Peptide-1 is secreted from enteroendocrine cells located in the ileum and colon in response to a meal. People with Type 2 sugar diabetes and impaired glucose tolerance are GPL-1 (glucagon-like Peptide-1) deficient. When given before a meal, exenatide (Byetta) restores first-phase insulin response in people with Type 2 diabetes. Exenatide reduces postprandial glucagon levels and increases insulin release from the beta cells. Exenatide (Byetta) injections improve gastric emptying and promotes satiety. It is noted that Byetta (exenatide) appears to reduce beta-cell death (apoptosis). Exenatide (Byetta) functions in a glucose-dependent fashion which means that the effects of the exenatide drug are obvious mainly in the presence of hyperglycemia. You can buy exenatide drug Byetta online now from various vendors following selected links to the right.

» Read more

Glucagon Like Peptide 1 Incretin Hormone. What is Glucagon Like Peptide 1?

Excessive food intake in patients with diabetes disease who are unable to reach normal body blood sugar level is thought to result in the production of incretin-antagonist hormones, leading to glucose intolerance and dysregulated insulin production in the pancreas. How to control blood sugar level. To control sugar level in blood body need to produce enough insulin to utilize excessive sugar. What is glucagon like peptide 1? Incretin hormones, such as glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide are hormones released from the small intestines in response to ingested food. Control of blood glucose levels works through join forces of insulin and glucagon like peptide 1 hormones.

» Read more